Clinical trials referenced in this document:
Documents that mention this clinical trial
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).
https://doi.org/10.1200/jco.2024.42.16_suppl.5510
Exploiting replicative stress in gynecological cancers as a therapeutic strategy
https://doi.org/10.1136/ijgc-2020-001277
Documents that mention this clinical trial
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
Exploiting replicative stress in gynecological cancers as a therapeutic strategy
https://doi.org/10.1136/ijgc-2020-001277
Documents that mention this clinical trial
Exploiting replicative stress in gynecological cancers as a therapeutic strategy
https://doi.org/10.1136/ijgc-2020-001277
Documents that mention this clinical trial
ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models
https://doi.org/10.1136/jitc-2023-007474
Exploiting replicative stress in gynecological cancers as a therapeutic strategy
https://doi.org/10.1136/ijgc-2020-001277
Documents that mention this clinical trial
Exploiting replicative stress in gynecological cancers as a therapeutic strategy
https://doi.org/10.1136/ijgc-2020-001277
Documents that mention this clinical trial
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types
https://doi.org/10.1007/s00280-020-04184-z
Exploiting replicative stress in gynecological cancers as a therapeutic strategy
https://doi.org/10.1136/ijgc-2020-001277
Funding for this research was provided by:
National Medical Research Council (CSAINV16may008)
National Medical Research Council (MOH-FLWSHP19may-0006)
This article is maintained by: Elsevier
Article Title: Exploiting replicative stress in gynecological cancers as a therapeutic strategy
Journal Title: International Journal of Gynecological Cancer
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/ijgc-2020-001277
Content Type: article
Copyright: Copyright © 2020 This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.